EUVIMEDEUVIMED entdecken
Kohortenstudie

Proton pump inhibitors and peritoneal dialysis‐associated peritonitis: a cohort study in Newcastle, Australia

Kate Richards iD, Eswari Vilayur

Internal Medicine Journal · 2025

DOI: 10.1111/imj.70128 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Kate Richards und 1 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology and Transplantation Unit, John Hunter Hospital, Newcastle, New South Wales, Australia. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Peritonitis, Peritoneal Dialysis. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peritoneal dialysis (PD)‐associated peritonitis results in poor outcomes, including hospitalisation, PD discontinuation and death. Proton pump inhibitors (PPIs) have been linked to an increased risk of organism‐specific and/or overall peritonitis in prior studies, yet they are commonly prescribed in the dialysis population.

Aims

To evaluate whether PPIs are associated with an increased risk of overall peritonitis in a local cohort.

Methods

We retrospectively identified patients with incident PD at a single Australian centre between 2012 and 2021. Baseline comorbidities, medications and PD outcomes were recorded. Patients were stratified by PPI exposure. We assessed whether PPI use affected time to first peritonitis using multivariate Cox proportional hazard modelling. The overall rate of peritonitis per patient‐year was compared between groups.

Results

Of 219 patients, 94 were exposed to PPIs, of whom 40 of 94 (42.6%) developed peritonitis, compared to 56 of 125 (44.8%) of the unexposed group. PPI use was not associated with time to first peritonitis in a multivariate Cox analysis (hazard ratio 0.78 (95% confidence interval 0.51–1.18), P = 0.2). The peritonitis rate was marginally lower in the PPI group. Atherosclerotic vascular disease was associated with peritonitis in an exploratory analysis.

Conclusions

PPI use was not associated with peritonitis risk in this cohort. Further work is needed to explain the discrepant findings between studies to date, including whether PPIs modulate the risk of peritonitis caused by specific organisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsPeritonitisPeritoneal DialysisHumansMaleFemaleMiddle AgedRetrospective StudiesAgedCohort StudiesAustraliaRisk Factors

Stichwörter der Autor:innen

cohort studyend stage kidney diseaseperitoneal dialysisperitonitisproton pump inhibitor

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Nephrology and Transplantation Unit, John Hunter Hospital, Newcastle, New South Wales, Australia.
  • School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.

ORCID-Profile: Kate Richards

Zitieren

APA

Richards, K., & Vilayur, E. (2025). Proton pump inhibitors and peritoneal dialysis‐associated peritonitis: a cohort study in Newcastle, Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.70128

Vancouver

Richards K, Vilayur E. Proton pump inhibitors and peritoneal dialysis‐associated peritonitis: a cohort study in Newcastle, Australia. Internal Medicine Journal. 2025. doi:10.1111/imj.70128

BibTeX
@article{Richards2025,
  author = {Richards, Kate and Vilayur, Eswari},
  title = {Proton pump inhibitors and peritoneal dialysis‐associated peritonitis: a cohort study in Newcastle, Australia},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.70128}
}
Kostenlos starten →